Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Dir SOL BARER Buys 20,000 Of MEDGENICS INC at 5.57 on 9/19
http://www.sec.gov/Archives/edgar/data/1138776/000114420413051582/xslF345X03/v355477_4.xml
Interview with Andrew Pearlman: (not new, short and oft misspelled ! )
President, Chief Executive Officer & Director
http://nbtequitiesresearch.com/sites/default/files/uploads/Medgenics_Inc_-_MDGN.pdf
Medgenics Awarded $1.9 Million Grant From The Israeli Office Of The Chief Scientist
http://jewishbusinessnews.com/2013/07/09/medgenics-awarded-1-9-million-grant-from-the-israeli-office-of-the-chief-scientist/
MDGN at JMP
Medgenics, Inc.
JMP Healthcare Conference
July 9, 2013 - July 10, 2013
The St. Regis - New York, NY
http://wsw.com/webcast/jmp21/MDGN/
or link from Co website
http://www.medgenics.com/
Medgenics Reports First Quarter 2013 Financial Results
MISGAV, Israel & SAN FRANCISCO, May 09, 2013 -- Medgenics, Inc. (nyse mkt:MDGN and AIM)(nyse mkt:MEDG) (the "Company"), the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today reported financial results for the three months ended March 31, 2013 and the filing with the U.S. Securities and Exchange Commission ("SEC") of the Company's Quarterly Report on Form 10-Q. The Form 10-Q includes unaudited interim consolidated financial statements containing the information presented below, as well as additional information regarding the Company. The Form 10-Q is available at and at .
Highlights of the First Quarter and recent weeks:
-- Raised gross proceeds of approximately $32 million in a public offering of common stock and warrants
-- Appointed Joseph J. Grano, Jr., former Chairman and CEO of UBS Financial Services, to the Company's Board of Directors
-- Received a Notice of Allowance from the U.S. Patent Office for claims that expand the patent protection for the Company's Biopump(TM) platform technology for additional therapeutic proteins
-- Reported interim results from the Company's ongoing Phase IIa study of EPODURE(TM) to treat anemia in dialysis patients
Management Commentary
"During the first quarter we achieved important milestones that strengthened our position in key areas and advanced our strategic and clinical goals," stated Andrew L. Pearlman, Ph.D., President and Chief Executive Officer of Medgenics. "We raised gross proceeds of approximately $32 million to strengthen our financial foundation, reported interim clinical results from our Phase IIa anemia trial in patients with end-stage renal disease, fortified our intellectual property and enhanced our Board of Directors with the appointment of Joseph J. Grano, Jr.
"We look forward to advancing our clinical studies in both Israel and the U.S. and to achieving a number of value-creating milestones throughout the remainder of 2013," concluded Dr. Pearlman.
First Quarter Financial Results
Gross research and development ("R&D") expense for the first quarter of 2013 increased to $2.03 million from $1.59 million for same period in 2012 due to an increase in R&D personnel. Net R&D expense for the 2013 first quarter was $2.03 million compared with net R&D expense of $0.57 million for the prior year's first quarter, when grants of $1.02 million were received from the Israel Office of the Chief Scientist.
General and administrative expense for the first quarter of 2013 was $2.55 million compared with $1.36 million for the first quarter of 2012, primarily due to increased stock-based compensation granted to directors and consultants.
Financial income for the first quarter of 2013 increased to $0.92 million from $0.02 million for the same period in 2012, mainly as a result of changes in valuation of the warrant liability.
For the quarter ended March 31, 2013, the Company reported a net loss of $3.68 million or $0.29 diluted loss per share, compared with a net loss of $2.71 million or $0.28 per share in the comparable 2012 period.
As of March 31, 2013, Medgenics had cash and cash equivalents of $32.46 million, compared with $6.43 million as of December 31, 2012. For the three months ended March 31, 2013, the Company used $2.80 million in net cash to fund operating activities, compared with $2.36 million for the three months ended March 31, 2012.
About Medgenics
Medgenics is developing and commercializing Biopump(TM), a proprietary tissue-based platform technology for the sustained production and delivery of therapeutic proteins using the patient's own tissue for the treatment of a range of chronic diseases including anemia, hepatitis and hemophilia, among others.
Forward-looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995, which include all statements other than statements of historical fact, including (without limitation) those regarding the Company's financial position, its development and business strategy, its product candidates and the plans and objectives of management for future operations. The Company intends that such forward-looking statements be subject to the safe harbors created by such laws. Forward-looking statements are sometimes identified by their use of the terms and phrases such as "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning, "expect," "believe," "will," "will likely," "should," "could," "would," "may" or the negative of such terms and other comparable terminology. All such forward-looking statements are based on current expectations and are subject to risks and uncertainties. Should any of these risks or uncertainties materialize, or should any of the Company's assumptions prove incorrect, actual results may differ materially from those included within these forward-looking statements. Accordingly, no undue reliance should be placed on these forward-looking statements, which speak only as of the date made. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, the events described in the forward-looking statements contained in this release may not occur.
MEDGENICS, INC. AND ITS SUBSIDIARY
(A Development Stage Company)
CONSOLIDATED BALANCE SHEETS
-----------------------------------------
U.S. dollars in thousands
March 31, December 31,
2013 2012
------------- --------------
Unaudited
-------------
ASSETS
CURRENT ASSETS:
Cash and cash equivalents $ 32,463 $ 6,431
Accounts receivable and prepaid expenses 572 539
------ ------
Total current assets 33,035 6,970
------ ------
LONG-TERM ASSETS:
Restricted lease deposits 45 62
Severance pay fund 229 283
------ ------
Total long-term assets 274 345
------ ------
PROPERTY AND EQUIPMENT, NET 350 352
------ ------
DEFERRED ISSUANCE EXPENSES - 40
------ ------
Total assets $ 33,659 $ 7,707
===== ====== ====== ======
MEDGENICS, INC. AND ITS SUBSIDIARY
(A Development Stage Company)
CONSOLIDATED BALANCE SHEETS
U.S. dollars in thousands
March 31, December31,
2013 2012
---------------- ----------------
Unaudited
----------------
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Trade payables $ 951 $ 877
Other accounts payable and accrued expenses 1,718 1,473
------- -------
Total current liabilities 2,669 2,350
------- -------
LONG-TERM LIABILITIES:
Accrued severance pay 1,429 1,492
Liability in respect of warrants 1,017 1,931
------- -------
Total long-term liabilities 2,446 3,423
------- -------
Total liabilities 5,115 5,773
------- -------
STOCKHOLDERS' EQUITY:
Common stock - $0.0001 par value; 2 1
100,000,000 shares authorized; 18,481,308 and 12,307,808 shares
issued and outstanding at March 31, 2013 and December 31, 2012,
respectively
Additional paid-in capital 96,797 66,509
Deficit accumulated during the development stage (68,255) (64,576)
------- --- ------- ---
Total stockholders' equity 28,544 1,934
------- -------
Total liabilities and stockholders' equity $ 33,659 $ 7,707
=== ======= === =======
MEDGENICS, INC. AND ITS SUBSIDIARY
(A Development Stage Company)
CONSOLIDATED STATEMENTS OF OPERATIONS
-----------------------------------------------------------------------------------------------------
U.S. dollars in thousands (except share and per share data)
Three months ended
March 31,
---------------------------------
2013 2012
Research and development expenses $ 2,031 $ 1,592
Less - Participation by the Office of the Chief Scientist - (1,022)
---------- --------- -
Research and development expenses, net 2,031 570
General and administrative expenses 2,546 1,359
---------- ---------
Operating loss (4,577) (1,929)
Financial expenses (14) (801)
Financial income 915 18
---------- ---------
Loss before taxes on income (3,676) (2,712)
Taxes on income 3 -
---------- ---------
Loss $ (3,679) $ (2,712)
====== ========== = ====== ========= =
Basic loss per share $ (0.24) $ (0.28)
====== ========== = ====== ========= =
$ (0.28)
Diluted loss per share $ (0.29)
====== ========== = ====== ========= =
15,222,268 9,753,725
========== =========
Weighted average number of Common stock used in computing basic loss
per share
Weighted average number of Common stock used in computing diluted 15,634,768 9,753,725
loss per share
====== ========== = ====== ========= =
SOURCE: Medgenics, Inc.
Medgenics, Inc.
Dr. Andrew L. Pearlman, +972 4 902 8900
andrew.pearlman@medgenics.com
or
LHA
Anne Marie Fields, 212-838-3777
afields@lhai.com
@LHA_IR_PR
or
Abchurch Communications
Adam Michael/Joanne Shears/Jamie Hooper
+44 207 398 7719
jamie.hooper@abchurch-group.com
or
Nomura Code Securities (NOMAD & Joint Broker)
Jonathan Senior/Giles Balleny
+44 207 776 1200
or
SVS Securities plc (Joint Broker)
Alex Brearley
+44 207 638-5600
Copyright Business Wire 2013
Medgenics Reports Positive Interim Results from Ongoing Phase IIa Study of EPODURE to Treat Anemia in Dialysis Patients
Biopump technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today provided an update on results from the first four patients treated thus far in its ongoing Phase IIa clinical trial in Israel of EPODURE™ Biopumps to treat anemia in patients on dialysis with end-stage renal disease (“ESRD”).
observations from the Company’s prior Phase I/II study in anemic pre-dialysis patients.
Hemoglobin in these patients remained in the desired 9-11 g/dl range for approximately 2-4 months, without needing any EPO or other ESA injections. Notably, at no point following EPODURE treatment did the concentration of EPO in the serum of the patients exceed the typical normal range and always remained under 100 mU/ml.
Patient compliance is a key to the success of this company. IMO...If (a big if) the bio-pump fulfills the potential and is approved it holds the promise to revolutionize protein therapy as we know it.
I know from personal experience that compliance is a major influence as to the effectiveness of any treatment. The bio-pump will, without question, improve patient compliance across all bio-pump platforms/indications.
I own a lump of MDGN stock. My investment in MDGN is based upon the platform, the management/board and my own personal belief (and my own DD) that the bio-pump could greatly improve the quality of life of MILLIONS cursed with protein issues.
Finally, if I financially gain from my speculative investment here then I know that Medgenics is on the way to improving life's...... and that is the type of profit that helps me sleep well at night!
Best of luck to everyone here supporting MDGN.
BMA
stox and warrants sale:$5.25
"Medgenics closes public offering of 5.6 mln shares of common stock and Series 2013-A warrants to purchase up to an aggregate of 2.8 mln shares of common stock (MDGN) 4.91 : The shares and the warrants were sold together as a fixed combination, each consisting of one share of common stock and a warrant to purchase one-half of a share of common stock, at a price to the public of $5.25 per fixed combination. The shares of common stock and warrants were issued separately. The warrants have an initial exercise price of $6.78, are currently exercisable and will expire on February 13, 2018."
Medgenics Launches First Clinical Trial in Hepatitis to Use INFRADURE Tissue Treatment
Phase I/II Study in Hepatitis C Expected to Provide Gateway to
Hepatitis B and D
MISGAV, Israel and SAN FRANCISCO (January 30, 2013) - Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the "Company"), the developer of a novel platform technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announced today that the first patient has been enrolled in a Phase I/II clinical trial with the Company's INFRADURE? Biopump? for the treatment of hepatitis C. This is the first clinical trial of INFRADURE, a subcutaneous autologous skin tissue implant for the continuous production and delivery of interferon-alpha (INFa) being developed by Medgenics to treat hepatitis B, C and D, aimed at replacing months of weekly injections of INFa, along with their serious side effects.
The Phase I/II dose-escalation study is being initiated at the Tel Aviv Sourasky Medical Center in Israel, with additional sites in Israel expected to join the study. The study is enrolling patients with hepatitis C of genotypes 2 and 3, who would normally receive weekly injections of pegylated INFa together with a daily dose of the oral antiviral drug ribavirin These patients will receive a single implantation of INFRADURE Biopumps in place of the weekly injections, together with daily ribavirin. The study is designed to show safety and tolerability of INFRADURE through the continuous delivery of INFa into the patient's circulation and to determine effective dose levels that suppress serum levels of hepatitis C virus. Medgenics believes that the results of this study will assist in developing and calibrating INFRADURE for use in additional types of viral hepatitis, as well as other indications.
INFRADURE is aimed at replacing injections of INFa to address a global market of over 500 million patients suffering from various forms of hepatitis. This proof of concept study will test INFRADURE's approach of continuous production of INFa from the patient's own dermal tissue. The INFRADURE treatment will be similar whether used in hepatitis C, hepatitis B, the most widespread form of hepatitis, or hepatitis D, a rare and highly aggressive form of the viral disease.
The current standard of care for treating hepatitis C involves weekly injections of pegylated INFa plus daily ribavirin. These weekly injections can be associated with high concentrations or spikes of INFa in patients, as well as significant side effects. These side effects pose considerable problems with patient compliance, as reflected in a therapy discontinuation rate of over 25%. INFa injections are also the primary treatment for hepatitis D and are often used in hepatitis B, where they pose similar problems. INFRADURE aims to address compliance and tolerability by providing sustained levels of INFa within the effective range for a sustained period from a single treatment, while avoiding high concentrations that are seen immediately following injections.
INFRADURE is the second product based on the Company's Biopump tissue-based platform to reach clinical trials in patients. INFRADURE employs the same approach as the Company's EPODURE? implant producing erythropoietin, which reported months of safe and sustained treatment of anemia from a single treatment in a Phase I/II study in patients with chronic kidney disease, replacing frequent erythropoietin injections.
About Hepatitis
Hepatitis is an inflammation of the liver and refers to a group of viral infections that affect that organ. The most common types are hepatitis A, hepatitis B and hepatitis C. Viral hepatitis is the leading cause of liver cancer and the most common reason for liver transplantation. Hepatitis B affects more than 350 million people worldwide and approximately 1.3 million in the U.S. Hepatitis D, an aggressive form of hepatitis, affects approximately 15-20 million people worldwide, and is estimated to afflict tens of thousands in the U.S. Hepatitis C affects an estimated 180 million people worldwide and over 3 million in the U.S.
About Medgenics
Medgenics is developing and commercializing Biopump?, a proprietary tissue-based platform technology for the sustained production and delivery of therapeutic proteins using the patient's own tissue for the treatment of a range of chronic diseases including anemia, hepatitis and hemophilia, among others. For more information, visit the Company's website at www.medgenics.com.
Forward-looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995, which include all statements other than statements of historical fact, including (without limitation) those regarding the Company's financial position, its development and business strategy, its product candidates and the plans and objectives of management for future operations. The Company intends that such forward-looking statements be subject to the safe harbors created by such laws. Forward-looking statements are sometimes identified by their use of the terms and phrases such as "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning, "expect," "believe," "will," "will likely," "should," "could," "would," "may" or the negative of such terms and other comparable terminology. All such forward-looking statements are based on current expectations and are subject to risks and uncertainties. Should any of these risks or uncertainties materialize, or should any of the Company's assumptions prove incorrect, actual results may differ materially from those included within these forward-looking statements. Accordingly, no undue reliance should be placed on these forward-looking statements, which speak only as of the date made. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, the events described in the forward-looking statements contained in this release may not occur.
Contacts:
Medgenics, Inc.
Dr. Andrew L. Pearlman, +972 4 902 8900
andrew.pearlman@medgenics.com
or
LHA
Anne Marie Fields, 212-838-3777
afields@lhai.com
@LHA_IR_PR
or
Abchurch Communications
Adam Michael/Joanne Shears/Jamie Hooper
+44 207 398 7719
jamie.hooper@abchurch-group.com
or
Nomura Code Securities (NOMAD & Joint Broker)
Jonathan Senior/Giles Balleny,
+44 207 776 1200
or
SVS Securities plc (Joint Broker)
Alex Mattey/Ian Callaway
+44 207 638 5600
# # #
To unsubscribe, click here or send an email to: ndarbinyan@lhai.com
absolutely nothing in the long term.
it was generic excerpt from a 42 page filing thats seen in every 8-k.
look for support and entry....!
The number of shares of our common stock that will be outstanding immediately after this offering is based on 12,307,808 shares of common stock outstanding as of December 31, 2012, and excludes:
1,059,542 shares of our common stock issuable upon the exercise of stock options outstanding under our Stock Incentive Plan as of December 31, 2012, at a weighted-average exercise price of $5.17 per share, 914,219 of which were exercisable as of that date;
900,000 shares of our common stock issuable upon the exercise of stock options granted to our Chairman of the Board outside of our Stock Incentive Plan, having an exercise price of $10.80 per share, 300,000 of which were exercisable as of that date;
929,152 shares of our common stock reserved for issuance under our Stock Incentive Plan as of December 31, 2012; 5,969,891 shares of our common stock issuable upon the exercise of outstanding warrants as of December 31, 2012, at a weighted-average exercise price of $5.93 per share, all of which were exercisable as of that date; and shares of our common stock issuable upon exercise of the Series 2013-A warrants to be issued in this offering.
Except as otherwise indicated, all information in this prospectus supplement assumes no exercise by the underwriters of their option to purchase additional shares and/or Series 2013-A warrants to cover over-allotments, if any.
gl
So what does this mean?
8K filed...
The report of our independent registered public accounting firm expresses substantial doubt about our ability to continue as a going concern.
Our auditors, Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, have indicated in their report on our financial statements for the fiscal years ended December 31, 2010 and 2011 that there exist conditions that raise substantial doubt about our ability to continue as a going concern due to recurring losses and the lack of working capital. We also expect to receive such a report for the fiscal year ended December 31, 2012. Early-stage biotechnical companies often receive such a report, as our continued operations are dependent on our ability to raise additional capital until revenues are available and received. A “going concern” opinion could impair our ability to finance our operations through the sale of debt or equity securities. Our ability to continue as a going concern will depend on our ability to obtain additional financing when necessary, which is not certain. If we are unable to achieve these goals, our business would be jeopardized and we may not be able to continue. If we ceased operations, it is likely that all of our investors would lose their investment.
We will need substantial additional capital for the continued development of our product candidates and for our long-term operations.
As of December 31, 2012, our cash and cash equivalents were approximately $6.4 million. Our present and future capital requirements depend on many factors, including:
· the level of patient recruitment in the phase IIa study of EPODURE in Israel, which will be commencing in the near term, as well as the anticipated clinical trials of INFRADURE in Israel, and the continuing results of such trials;
· the level of preparations for our anticipated phase IIb study of EPODURE in the United States;
· the level of research and development investment required to develop our first product candidates, and maintain and improve the Biopump Platform Technology;
· changes in product development plans needed to address any difficulties that may arise in manufacturing, preclinical activities, clinical studies or commercialization;
· our ability and willingness to enter into new agreements with strategic partners, and the terms of these agreements;
· our success rate in preclinical and clinical efforts associated with milestones and royalties;
· the costs of recruiting and retaining qualified personnel;
· the time and costs involved in obtaining regulatory approvals; and
· the costs of filing, prosecuting, defending, and enforcing patent claims and other intellectual property rights.
We will require significant amounts of additional capital in the future, and such capital may not be available when we need it on terms that we find favorable, if at all. We may seek to raise these funds through public or private equity offerings, debt financings, credit facilities, or partnering or other corporate collaborations and licensing arrangements. If adequate funds are not available or are not available on acceptable terms, our ability to fund our operations, take advantage of opportunities, develop products and technologies, and otherwise respond to competitive pressures could be significantly delayed or limited, and we may need to downsize or halt our operations.
We have significant severance liabilities and may not be able to satisfy such obligations.
Our balance sheet as of September 30, 2012 includes a net liability of approximately $1.31 million representing severance payments required under Israeli law and contractual obligations in excess of severance covered by our current insurance policies that would be due if our employees left under circumstances that triggered payment of severance. Of such amount, approximately $0.59 million represents amounts that would be payable to our President and Chief Executive Officer if his employment with us terminated.
Our liability for severance pay is calculated pursuant to the Israeli severance pay law based on the most recent salary for the employees multiplied by the number of years of employment, as of the balance sheet date. Under law, employees are entitled to one month salary (based on the average of the employee’s last three months’ salary) for each year of employment or a portion thereof. Accordingly, our unfunded severance liability increases upon any increase in an employee’s salary. In addition, several employees are entitled to additional severance compensation in accordance with the terms of their respective employment agreements. Our liability for all of our employees is fully provided by an accrual and is mainly funded by monthly deposits with insurance policies. The value of these policies is recorded as an asset in our balance sheet. Our net liability for severance payments is due to additional months of severance provided under our agreements with certain employees and to any shortfall in our deposited amounts caused by increases in salary.
The deposited funds may be withdrawn only upon the fulfillment of the obligation pursuant to Israeli severance pay law or labor agreements. The value of the deposited funds is based on the cash surrender value of these policies and includes profits or losses as appropriate.
We are still in the process of clinical trials and do not have a commercialized product and may never be able to commercialize our product candidates.
We have completed a phase I/II clinical trial with respect to our EPODURE Biopump in pre-dialysis patients and are conducting a phase IIa study in dialysis patients in Israel and preparing for a phase II study in dialysis patients in the United States. We have not commenced clinical trials for our INFRADURE Biopump or any other Biopump application. Only a small number of research and development programs ultimately result in commercially successful drugs and drug delivery systems. Potential products that appear to be promising at early stages of development may not reach the market for a number of reasons, including:
· failure to obtain approvals for large-scale clinical trials;
· difficulties related to large-scale manufacturing;
· lack of familiarity of health care providers and patients;
· low market acceptance as a result of lower demonstrated clinical safety or efficacy compared to other products or other potential disadvantages relative to alternative treatment methods;
· inability to obtain favorable coverage determinations from health plans and third-party payers;
· insufficient or unfavorable levels of reimbursement from government or third-party payers;
· infringement on proprietary rights of others for which we (or our licensees, if any) have not received licenses;
· incompatibility with other therapeutic products;
· potential advantages of alternative treatment methods;
· ineffective marketing and distribution support;
· lack of cost-effectiveness; or
· timing of market introduction of competitive products.
If any of these potential problems occurs, we may never successfully commercialize our Biopump Platform Technology. If we are unable to develop commercially viable products, our business, results of operations and financial condition will be materially and adversely affected.
Our Biopump Platform Technology is still being developed and has not been tested on a large scale, and, therefore, we do not know all of the possible side effects and may not be able to commercialize our technology as planned.
The Biopump Platform Technology has not been tested on a large scale, and is still in an early stage of development. Although we and our advisors believe that the results in patients treated to date have demonstrated proof of concept and shown safety and efficacy of our technology so far in its first application, and although we are encouraged by the FDA clearance to proceed with a Phase IIb anemia study with EPODURE in dialysis patients, this does not constitute confirmation or approval of the safety and efficacy of our technology, nor have we received such from any regulatory authority. To date, although we have produced thousands of Biopumps in the laboratory, we have administered Biopumps to only a relatively small number of patients. We are in the early stages of developing the most efficient and effective methods to implant Biopumps so as to attain sustained performance once in the patient and thereby produce the desired therapeutic effect for extended periods of time. While we have attained a number of positive results in our first clinical application, there is significant variability between patients. These and other aspects of the implementation and use of the Biopump Platform Technology are not yet fully developed or proven, and disappointing results and problems could delay or prevent their completion. Even if the Biopump Platform Technology works well in one indication, it could have disappointing results in others. If so, the development could be stalled or even blocked in one or more indications. Potential risks associated with the use of the Biopump Platform Technology are the development of an immune response to the vector or the encoded protein product, local inflammatory response to the implanted tissue or associated with the insertion of the Biopump in the surrounding tissue, autoimmunity to the endogenous protein product or potential overdose of protein due to difficulties in managing the continuous supply in the patient in accordance with patient need. Risk for immunogenic reaction to the vector is based on clinical studies using first general adenoviral vectors that contain a full complement of viral proteins. We currently use a gutless adenoviral vector in all our development activities and our current trial to eliminate the risk of immune rejection of the Biopumps prepared with viral vector particles. While these gutless adenoviral vectors do not include genes for viral proteins, the risk for somehow re-establishing expression of viral proteins cannot be ruled out.
The basis for the risks described above is currently only theoretical since these effects have not been seen in the small number of patients that have received a Biopump in our EPODURE clinical trials or in preclinical safety studies performed in mice. However, the possible side effects and full efficacy and safety of the technology need to be tested in a substantial number of patients to verify this. Our previous safety tests were only carried out on a small number of patients and therefore any conclusions may not be representative of either a larger multi-centric test or the commercial version of the technology in the general population. In addition, the full impact of the technology, and its many possible variations, on the body is, as yet, unknown. Although no side effects attributed to the Biopump Platform Technology were found to date in our EPODURE clinical trials, other than minor bruising at the implantation site, the possibility cannot be ruled out that serious side effects might be borne out by further trials, and if so, this could have serious implications on the viability of the technology and our business.
Although the Biopump Platform Technology aims to minimize the residual number of viral vector particles and their proteins introduced into a body, there is a chance that the cumulative effect of Biopump reimplantation could result in an eventual buildup of viral proteins and an immunogenic reaction against the Biopumps preventing further implantations, which could question the viability of the technology.
Severe side effects or complications in trials, or post-approval, could result in financial claims and losses against us, damage our reputation, and increase our expenses and reduce our assets. In addition, our product candidates may not gain commercial acceptance or ever be commercialized.
We are completely dependent upon the successful development of our Biopump Platform Technology. If we fail to successfully complete its development and commercialization or enter into licensing or partnership agreements, we will not generate operating revenues.
All of our efforts are focused on the development of our Biopump Platform Technology. There is no guarantee that we will succeed in developing products based on our Biopump Platform Technology. If we or any partner(s) or collaborator(s) that we may enter into a relationship with are unable to consummate the production of Biopumps to provide the sustained protein therapy to treat various chronic diseases in a safe, stable, commercial end-product form, we will be unable to generate any revenues. There is no certainty as to our success, whether within a given time frame or at all. Any delays in our schedule for clinical trials, regulatory approvals or other stages in the development of our product are likely to cause us additional expense, and may even prevent the successful finalization of any or all of our product candidates. Delays in the timing for development of our technology may also have a material adverse effect on our business, financial condition and results of operations due to the possible absence of financing sources for our operations during such additional periods of time.
Clinical trials involve lengthy and expensive processes with uncertain outcomes, and results of earlier studies and trials may not be predictive of future trial results.
We cannot predict whether we will encounter problems with any of our completed, ongoing or planned clinical trials, which would cause us or regulatory authorities to delay or suspend clinical trials, or delay the analysis of data from completed or ongoing clinical trials. We estimate that clinical trials involving various applications of our Biopump Platform Technology will continue for several years; however, such trials may also take significantly longer to complete and may cost more money that we expect. Failure can occur at any stage of testing, and we may experience numerous unforeseen events during, or as a result of, the clinical trial process that could delay or prevent commercialization of the current, or a future, more advanced, version of our Biopump Platform Technology, including but not limited to:
· delays in obtaining regulatory approvals to commence a clinical trial;
· failure or inability to recruit qualified investigators;
· slower than anticipated patient recruitment and enrollment;
· negative or inconclusive results from clinical trials;
· unforeseen safety issues;
· an inability to monitor patients adequately during or after treatment; and
· problems with investigator or patient compliance with the trial protocols.
A number of companies in the medical device, biotechnology, and biopharmaceutical industries, including those with greater resources and experience than us, have suffered significant setbacks in advanced clinical trials, even after seeing promising results in earlier clinical trials. Despite the successful results reported in early clinical trials regarding our EPODURE Biopump, we do not know whether any clinical trials we or our clinical partners may conduct will demonstrate adequate efficacy and safety to result in regulatory approval to market our product candidate for the treatment of chronic kidney disease or other indications. If later-stage clinical trials involving EPODURE Biopump do not produce favorable results, our ability to obtain regulatory approval may be adversely impacted, which will have a material adverse effect on our business, financial condition and results of operations.
Medgenics Granted U.S. Patent for Core Technology Used in Sustained Delivery of Erythropoietin, Aimed at Multi-Billion Dollar Anemia Market
Medgenics files shelf registration (MDGN) 9.08 : The aggregate offering price of all securities that may be sold under the registration statement will not exceed $150 mln. The shelf registration statement is intended to give co additional flexibility to finance business opportunities in the future by accessing the capital markets on a timely and cost effective basis.
Agree, I thought they would have done this earlier. But this was expected.
Gl
Lots of insider selling... now a $ 150M shelf. Does anyone know their latest cash position and their burn rate?
Glad I held off on this. I'll get in after the raise.
The attached Press Release was issued on August 29, 2012
Medgenics' Novel Tissue Implant Approved for Two Hepatitis C Clinical Trials in Israel
First in man clinical trials of INFRADURE Biopumps for the continuous production of interferon alpha from patient's own tissue
Gl
This is about to fly. Check out this report:
http://finance.yahoo.com/news/why-accumulating-trading-shares-medgenics-104702741.html
good volume.
company has generated interest and eincreased exposure.
nicely done
gl
10:37AM Medgenics announces launch of its Phase IIa clinical trial in Israel of EPODURE Biopumps to treat anemia in patients with end-stage renal disease on dialysis (MDGN) 14.65 -0.45 : Following the Israeli Ministry of Health's recent approval of the trial, Medgenics has enrolled and begun to treat the first two dialysis patients ever to receive EPODURE Biopumps. Enrollment is expected to continue in the coming months, with up to 20 patients being treated with EPODURE Biopumps. The study will evaluate the ability of EPODURE Biopumps to replace most or all of the injections of EPO or other erythropoietic stimulating agents currently used in standard care, while maintaining the patient's blood hemoglobin level within the desired range. For the first two patients in the current study, the EPODURE procedure has gone well, as in the previous study, and EPO concentrations were confirmed to be elevated within normal range in the patients' blood in the days following EPODURE administration. This is consistent with the Phase I/Phase II findings, which indicated that EPODURE Biopumps were delivering EPO in the patients. Moving forward, patients will be followed to determine how long their hemoglobin levels remain in the desired range while EPO levels remain within normal range.
Medgenics Inc (NYSE:MDGN) chief executive Dr. Andrew Pearlman claims its Biopump technology could possibly “start a whole new pharmaceutical industry. Our technology has promise to provide a major change in medicine. It is not just a product that we have, it’s an industry.” The technology manipulates the tissue of the patients themselves in order to produce proteins which fight diseases. This will eliminate the necessity for hundreds of vaccines. Shares of Medgenics Inc are trading 6.67% lower today.
Part of there Investor Relations CD packet.
few updates.
gl
not sure if this is a new presentation or not (seems like it is as it is dated as of today):
http://www.proactiveinvestors.co.uk/genera/files/companies/3._medgenics_presentation__july_5_2012_main_presentation_final.pdf
i like what i see, and those who remember Inhibitex may also see the bluesky potential for MDGN - story just getting discovered.
Medgenics Inc (MDGN) climbed over 43% after analysts Sharon di Stefano and Ray Dirks, long-time observers of new chairman, Sol Barer`s career put out bullish notes on the firm. di Stefano, who watched the former chairman and CEO of Celgene Corp. (CELG) build that company into a multi-billion dollar biotech powerhouse and Driks recognized the latest development at Medgenics and believe the cost-effectiveness of MDGN`s products all point to significant future shares in multiple sizeable markets.
Great volume, someone wants in!
long way to go, take some basis of the books.
gl all
anything under $5 looks pretty good!:)
who would have ever known!
gl
WORDS FROM THE CEO
In near record time, Andrew L. Pearlman, Ph.D., President and Chief Executive Officer of Medgenics (MDGN) has helped position his relatively new publicly traded company at a much higher level-- one that most other biotech firms usually take far longer to reach.
Earlier this week on Tuesday, his firm raised $9.5 million via a Private Placement and twenty-four hours later, he announced that Medgenics` INFRADURE(TM) for the treatment of hepatitis D had received Orphan Drug Designation from U.S. regulators at the FDA.
The significant news effectively made every protein therapy and hepatitis drug developer (not to mention investors) looks up and take notice.
"We see this as a really significant validation of our technology by the world`s toughest regulatory agency," explains Pearlman. "This coming literally just a month after the FDA approved our first clinical trials- which went straight to Phase IIB- in the United States."
Asked to explain the significance of having achieved this designation for Medgenics` proprietary tissue-based Biopump(TM) platform, Pearlman doesn`t miss a beat.
"First of all, Orphan Status is a very really significant milestone for any company in pharma or biotechnology," Pearlman says. "Because Orphan Drug Status means that the FDA recognizes that the treatment that you`re developing is promising and looks like it can address the need for a specific patient population base."
Medgenics has been diligently developing the same proprietary tissue-based Biopump(TM) platform technology for the sustained production and delivery of therapeutic proteins using the patient`s own skin biopsy for the treatment of a range of chronic diseases including anemia, hepatitis C and hemophilia among others. Pearlman believes this approach has multiple benefits compared with current treatments, which include regular and costly injections of therapeutic proteins and if he`s right, his firm may have just taken one giant step toward convincing the rest of the world he was right.
"The reason why this is so important for our Company is that this is the first Orphan designation that we`ve attained for the use of our Biopump(TM) system and the beauty of this situation for us is that with Orphan designation, often what happens is that firms are granted an accelerated approval path by the FDA and although that`s not guaranteed, we feel we have a good chance and are certainly hoping for that. Also, after a designation like this, the actual size of the clinical trials one needs to conduct is usually considerably smaller than you have to do for any of the major indications," says Pearlman.
"In Israel, we are hoping to be approved to commence the studies of our Biopump(TM) technology in Hepatitis C. Now Hepatitis C is an enormous indication. One hundred and eighty million people in the world have it and the INFRADURE Biopump(TM) has a very appealing and advantageous value proposition for the treatment of hepatitis C. It has an even more, I would say, compelling case for treating hepatitis B and there are some 350 million patients in the world with hepatitis B. All of these indications would use the same INFRADURE Biopump(TM) approach. The Biopump(TM) stimulates your body`s immune system to fight the viral infection- whether its hepatitis B, C or D. The advantage of the combined approach that we`re doing in going after hepatitis D as an orphan drug in the United States while commencing the clinical testing in hepatitis C in Israel is that we believe that we will demonstrate safety and efficacy in both of these indications, but that in the case of hepatitis D, there is a very improved likelihood for a relatively rapid route to a product approval compared to hepatitis B or hepatitis C-in which there would likely be much larger clinical trials and a longer path toward approval."
Following a late morning confirmation about the FDA news, shares of the company soared 25.36% to $8.65 +1.75 during regular market hours and headed higher in early trading on Thursday. If trading has been any indication thus far, the low-float stock may continue to appreciate in value as the market continues to digest the significance of the news. Particularly since some of Big Pharma`s recent buyouts have targeted Drug makers developing hepatitis treatments.
Even some which have shown, arguably, less promise and innovation than Medgenics` own novel platform-- which aims to reduce some of the terrible side effects many patients endure with other treatments-have been acquired at huge premiums
Pearlman is focused on making sure that his firm will continue to build its pipeline and add value beyond its current $83.73 million market cap by executing and continuing to share positive developments like this one with investors.
"This is now the second approval that we`ve gotten for our technology, for our company and we think it will give a lot more confidence to would-be partners and institutional investors who may have been looking for a clear sign from a regulatory agency that we have a straight shot for an approvable product within a reasonable time."
Medgenics Inc. Commo (MDGN) rises quickly following the company’s announcement that its Infradure Biopump has been given an Orphan Drug Designation from the FDA in order to treat hepatitis D. This designation allows the company to be given grant money, obtain specific tax credits, seven years of market exclusivity, and possibly an expedited regulatory process. The designations has made Seeking Alpha contributor Ray Dirks label Medgenics as a prime takeout target. The shares closed at $8.65, up $1.75 or 25.36% on the day. They have traded in a 52-week range of $2.08 to $8.60
i am impressed!
great day!
cheers to all even those with one foot in and one foot out:)
MDGN Orphan Drug Approval For Medgenics' Hepatitis Therapy Makes It Big Pharma Target
June 20, 2012 | 1 comment | about: MDGN, includes: ABT, ACHN, BMY, GILD, IDIX, MRK, VRTX
Drugs to treat the hepatitis virus are quickly becoming the hottest area of medicine. Recent buyouts include Gilead Sciences (GILD) paying $11 billion in cash for Pharmasset and Bristol-Myers Squibb (BMY) snagging Inhibitex for $2.5 billion in cash. Other key players in the space include Idenix Pharmaceuticals (IDIX), Achillion Pharmaceuticals (ACHN), Abbott Laboratories (ABT), Vertex Pharmaceuticals (VRTX) and Merck & Co. (MRK).
No wonder that large biotechs are looking to buy - hepatitis viruses, grouped as A, B, C, and D, are considered a worldwide epidemic and highly contagious. The World Health Organization (WHO) puts the number of those infected at 550 million, or nearly 8% of the entire human population. Almost 70% of people advance to a chronic state. It is the number one reason for liver cancer. There is no cure.
Which brings us to - Medgenics (MDGN) announcing an Orphan Drug Designation for its INFRADURE for the treatment of hepatitis D. Orphan Drug Designation means smaller clinical trials and faster approval time.
This announcement follows an astounding run of good news for Medgenics including FDA approval of an Investigational New Drug (IND) application for its EPODURE device for anemia and the launch of a US-based manufacturing facility for its Biopump, the company, making good on our prediction of a highly-favorable relationship with the FDA.
Also, good results would pave the way for hepatitis C trials in the US and for final approval for hepatitis D in Israel. Hepatitis D affects 15 million people worldwide. Hepatitis C is a larger market at 180 million, and we envision INFRADURE serving as a platform technology to launch all versions of treatment for the hepatitis virus.
Timing is excellent for MDGN. Drug makers for hepatitis are being snatched up at huge premiums, and companies that are already in the market are seeing sales on the blockbuster level.
A new and better treatment entering clinical trials for hepatitis should propel MDGN's market cap far beyond its current $69 million. Even its closest competitor, ACHN, is trading at a market capitalization of $471 million and doesn't have nearly as full a pipeline as MDGN. Same for IDIX: with only three drugs in the pipeline, its market cap is over $1 billion.
We think Medgneics is on the radar of drug makers and biotechnology outfits that are scrambling to tap into this $20 billion market, causing a rise in M&A activity and new stock highs for the publicly-traded companies involved.
Last November, Gilead Sciences paid $137 per share, or $11 billion in cash, for Pharmasset, an 89% premium to the stock price, making a big bet on a new generation of drugs to combat Hepatitis C. Two months later, Bristol-Myers Squibb snagged Inhibitex for $2.5 billion in cash, a premium of 163% to the price of the shares. Although partnerships are more common for drugs in mid-stage clinical trials, both companies chose a buy-out strategy to gain full control of the potential blockbusters.
Investors feel the excitement and have been paying close attention to other makers of hepatitis drugs. Idenix Pharmaceuticals is advancing two compounds for hepatitis through clinical trials. Achillion Pharmaceuticals received Fast Track designation from the FDA for its treatment for chronic hepatitis C which is currently in Phase I. Abbott Laboratories announced promising results for its hepatitis drug, with predictions of $2 billion in annual sales upon approval and commercialization.
Companies with new versions of hepatitis treatments are clearing the way for new classes of compounds expected to enter the market over the next five years. Vertex Pharmaceuticals sells INCIVEK, a recently-approved hepatitis C combination therapy that was co-developed with Merck & Co. and was the first new drug on the market for hepatitis in almost 10 years. Sales for the drug were $420 million last year.
Demand for a new drug regimen for the virus is high. PEG-interferon and ribavirin are known for low efficacy, long treatment times, and terrible side effects. Many patients feel the treatment is worse than the disease itself. Medicine is ripe with the anticipation of newer, better drugs and doctors are more than willing to veer away from the long-time standard of care.
Ray Dirks Research recommended MDGN in February when it was trading at $3.50 per share. Shares have risen 244% since then and it's only the beginning. With a path to fast regulatory approval for treating a incurable condition in a huge medical market, not to mention progress with its Biopump therapy in anemia, multiple sclerosis, arthritis, hemophilia, pediatric growth hormone deficiency, obesity, diabetes, and other chronic diseases, shares of MDGN should be bought at this very attractive price.
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
http://bit.ly/Pe6PYn
BIG PHARMA TARGET
Drugs to treat the hepatitis virus are quickly becoming the hottest area of medicine. Recent buyouts include Gilead Sciences (GILD) paying $11 billion in cash for Pharmasset and Bristol-Myers Squibb (BMY) snagging Inhibitex for $2.5 billion in cash. Other key players in the space include Idenix Pharmaceuticals (IDIX), Achillion Pharmaceuticals (ACHN), Abbott Laboratories (ABT), Vertex Pharmaceuticals (VRTX) and Merck & Co. (MRK).
No wonder that large biotechs are looking to buy - hepatitis viruses, grouped as A, B, C, and D, are considered a worldwide epidemic and highly contagious. The World Health Organization (WHO) puts the number of those infected at 550 million, or nearly 8% of the entire human population. Almost 70% of people advance to a chronic state. It is the number one reason for liver cancer. There is no cure.
Which brings us to - Medgenics (MDGN) announcing an Orphan Drug Designation for its INFRADURE for the treatment of hepatitis D. Orphan Drug Designation means smaller clinical trials and faster approval time.
This announcement follows an astounding run of good news for Medgenics including FDA approval of an Investigational New Drug (IND) application for its EPODURE device for anemia and the launch of a US-based manufacturing facility for its Biopump, the company, making good on our prediction of a highly-favorable relationship with the FDA.
Also, good results would pave the way for hepatitis C trials in the US and for final approval for hepatitis D in Israel. Hepatitis D affects 15 million people worldwide. Hepatitis C is a larger market at 180 million, and we envision INFRADURE serving as a platform technology to launch all versions of treatment for the hepatitis virus.
Timing is excellent for MDGN. Drug makers for hepatitis are being snatched up at huge premiums, and companies that are already in the market are seeing sales on the blockbuster level.
A new and better treatment entering clinical trials for hepatitis should propel MDGN's market cap far beyond its current $69 million. Even its closest competitor, ACHN, is trading at a market capitalization of $471 million and doesn't have nearly as full a pipeline as MDGN. Same for IDIX: with only three drugs in the pipeline, its market cap is over $1 billion.
We think Medgneics is on the radar of drug makers and biotechnology outfits that are scrambling to tap into this $20 billion market, causing a rise in M&A activity and new stock highs for the publicly-traded companies involved.
Last November, Gilead Sciences paid $137 per share, or $11 billion in cash, for Pharmasset, an 89% premium to the stock price, making a big bet on a new generation of drugs to combat Hepatitis C. Two months later, Bristol-Myers Squibb snagged Inhibitex for $2.5 billion in cash, a premium of 163% to the price of the shares. Although partnerships are more common for drugs in mid-stage clinical trials, both companies chose a buy-out strategy to gain full control of the potential blockbusters.
Investors feel the excitement and have been paying close attention to other makers of hepatitis drugs. Idenix Pharmaceuticals is advancing two compounds for hepatitis through clinical trials. Achillion Pharmaceuticals received Fast Track designation from the FDA for its treatment for chronic hepatitis C which is currently in Phase I. Abbott Laboratories announced promising results for its hepatitis drug, with predictions of $2 billion in annual sales upon approval and commercialization.
Companies with new versions of hepatitis treatments are clearing the way for new classes of compounds expected to enter the market over the next five years. Vertex Pharmaceuticals sells INCIVEK, a recently-approved hepatitis C combination therapy that was co-developed with Merck & Co. and was the first new drug on the market for hepatitis in almost 10 years. Sales for the drug were $420 million last year.
Demand for a new drug regimen for the virus is high. PEG-interferon and ribavirin are known for low efficacy, long treatment times, and terrible side effects. Many patients feel the treatment is worse than the disease itself. Medicine is ripe with the anticipation of newer, better drugs and doctors are more than willing to veer away from the long-time standard of care.
Ray Dirks Research recommended MDGN in February when it was trading at $3.50 per share. Shares have risen 244% since then and it's only the beginning. With a path to fast regulatory approval for treating a incurable condition in a huge medical market, not to mention progress with its Biopump therapy in anemia, multiple sclerosis, arthritis, hemophilia, pediatric growth hormone deficiency, obesity, diabetes, and other chronic diseases, shares of MDGN should be bought at this very attractive price.
http://seekingalpha.com/article/672371-orphan-drug-approval-for-medgenics-hepatitis-therapy-makes-it-big-pharma-target?source=yahoo
"Each Unit was sold for a purchase price of $4.90 to institutional and other accredited investors in a private placement transaction. The Warrants expire in five years, have an initial exercise price of $8.34 per full share and become first exercisable on December 15, 2012. "
excerpt...
spoke too soon, lets see how this holds support.
gl
Stox and warrants sale @$4.90 ; we know bottom rock price now! : "Medgenics raises $9.5 mln in private placement (MDGN) 6.95 : Co announced it has raised gross proceeds of a~ $9.5 mln (~ $8.4 mln net) through the sale of 1,944,734 units, with each Unit consisting of one share of the Company's Common Stock, $0.0001 par value per share, and a warrant to purchase 0.75 of one share of Common Stock. Each Unit was sold for a purchase price of $4.90 to institutional and other accredited investors in a private placement transaction. The Warrants expire in five years, have an initial exercise price of $8.34 per full share and become first exercisable on December 15, 2012. Medgenics intends to use the proceeds from this private placement to further its clinical trial programs for its EPODURE Biopump producing erythropoietin for the treatment of anemia, and its INFRADURE Biopump producing interferon-alpha for the treatment of hepatitis, as well as for other research and development, patent maintenance and other intellectual property support and general corporate purposes. Maxim Group LLC acted as the exclusive placement agent for the private placement."
those who bought in the sub $5 gamble, are looking good.
the only thing that scares me about this stock, is the small float at 6.89 million (with a lot of room to dilute), and unclear finances to complete beyond phase 2 to the end has been keeping one foot out the door.
if the company elaborates on this more clearly (positive), this may fly!
gl
holding reasonably well, with good volume during a down market.
gl all
This is good news... waiting for this one.
Medgenics receives FDA clearance to commence Phase IIb trial of EPODURE for sustained anemia treatment in dialysis patients (MDGN) 5.65 +0.15 : The FDA cleared the Phase IIb study protocol based on results from the Company's prior Phase I/II anemia study of EPODURE in Israel, which reported safety and maintenance of hemoglobin for months from a single EPODURE treatment in pre-dialysis patients without requiring injections of EPO or ESAs, as well as on the complete preclinical package. The Company was particularly encouraged that clearance was received within the 30-day required regulatory response period from submission of the IND application and without major issues being raised. Medgenics views this as an early, second validation from an independent critical review in the U.S. of its Biopump platform.
First quarter financials out.
fairly even. which is typically is poor, but for a developmental company pretty good.
gl
Spinning, no.....
A small stake at $5. (Was waiting for the biomedreport crowd to sell off), and the $4 range offered good support.
The potential is huge, and finally they are beginning to unfold there plan.
Right now its all about the data!
Gl. And hope it takes more for your head to spin!
from $4.00 to $8.00 I would think your eyes would be spinning if you are in ..lol
Medgenics files for U.S. Orphan Drug Designation for INFRADURE for the treatment of Hepatitis D (MDGN) 5.365 +0.01 : Co announced that it has filed for Orphan Drug Designation with the FDA for INFRADURE for the treatment of hepatitis D. INFRADURE is based on Medgenics' proprietary tissue-based Biopump platform technology, which uses the patient's own tissue to continuously produce and deliver therapeutic proteins, such as interferon-alpha for use in the treatment of hepatitis. Medgenics expects to receive the FDA's initial response to the filing before the end of this quarter, and believes Orphan Designation could be confirmed during the third quarter.
10:16AM Medgenics files Investigational New Drug application for Epodure Biopump Phase 2b anemia study in dialysis patients (MDGN) 4.50 +0.01 : Co announced that it has filed an Investigational New Drug application with the FDA to initiate a Phase IIb multi-center, 100-patient clinical trial. The trial is designed to evaluate the safety and efficacy of sustained erythropoietin therapy delivered via the co's EPODURE Biopump for the treatment of anemia in dialysis patients with end-stage renal disease.
Followers
|
5
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
125
|
Created
|
02/08/12
|
Type
|
Free
|
Moderators |
About Medgenics, Inc.
Medgenics is developing TARGT™ (Transduced Autologous Restorative Gene Therapy), a proprietaryex vivo gene therapy platform for the sustained production and delivery of therapeutic proteins and peptides using a patient's own tissue, for the treatment of rare and orphan diseases. For more information, visit the Company's website at www.medgenics.com.
Our core strategy is based upon three fundamental strengths:
TECHNOLOGY:Transduced Autologus Restorative Gene Theraphy |
| | | ||
|
|
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |